Details

Autor(en) / Beteiligte

• Levin, Theodore R.
• Corley, Douglas A.
• Jensen, Christopher D.
• Marks, Amy R.
• Zhao, Wei K.
• Zebrowski, Alexis M.
• Quinn, Virginia P.
• Browne, Lawrence W.
• Taylor, William R.
• Ahlquist, David A.
• Lidgard, Graham P.
• Berger, Barry M.

Titel

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue

Ist Teil von

• Digestive diseases and sciences, 2017-03, Vol.62 (3), p.678-688

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Fecal immunochemical test (FIT) screening detects most asymptomatic colorectal cancers. Combining FIT screening with stool-based genetic biomarkers increases sensitivity for cancer, but whether DNA biomarkers (biomarkers) differ for cancers detected versus missed by FIT screening has not been evaluated in a community-based population. Aims To evaluate tissue biomarkers among Kaiser Permanente Northern California patients diagnosed with colorectal cancer within 2 years after FIT screening. Methods FIT-negative and FIT-positive colorectal cancer patients 50–77 years of age were matched on age, sex, and cancer stage. Adequate DNA was isolated from paraffin-embedded specimens in 210 FIT-negative and 211 FIT-positive patients. Quantitative allele-specific real-time target and signal amplification assays were performed for 7 K-ras mutations and 10 aberrantly methylated DNA biomarkers ( NDRG4 , BMP3 , SFMBT2_895 , SFMBT2_896 , SFMBT2_897 , CHST2_7890 , PDGFD , VAV3 , DTX1 , CHST2_7889 ). Results One or more biomarkers were found in 414 of 421 CRCs (98.3%). Biomarker expression was not associated with FIT status, with the exception of higher SFMBT2_897 expression in FIT-negative (194 of 210; 92.4%) than in FIT-positive cancers (180 of 211; 85.3%; p  = 0.02). There were no consistent differences in biomarker expression by FIT status within age, sex, stage, and cancer location subgroups. Conclusions The biomarkers of a currently in-use multi-target stool DNA test ( K - ras , NDRG4 , and BMP3 ) and eight newly characterized methylated biomarkers were commonly expressed in tumor tissue specimens, independent of FIT result. Additional study using stool-based testing with these new biomarkers will allow assessment of sensitivity, specificity, and clinical utility.